Content area
Full text
Both Ranbaxy Pharmaceuticals and Apotex last month received tentative approval to manufacture and market pravastatin sodium tablets, the generic equivalent of Bristol-Myers Squibb's cholesterol-lowering Pravachol. Sales for Pravachol reached $1.9 billion for the 12 months ended in June, according to IMS Health data.
Geneva, Ivax, Lek and Teva also have tentative approvals to market pravastatin.
In September, Ranbaxy also was tentatively approved to market a generic equivalent to Merck's Zocor (simvastatin), the No. 2 statin on the market with sales of $4.2 billion for the 12 months ended in June.
Barr Laboratories last month signed a letter of intent to acquire the emergency oral contraceptive Plan B and certain other assets and liabilities of the Women's Capital Corp. Financial terms of the prospective acquisition were not disclosed.
"As a...